Observational studyPloS one2014

Moving away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE)--agents that concern prescribers and patients: a feasibility study and call for a trial.

Amit C Achhra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.